Established Efficacy in Patients with SLE
BENLYSTA IS THE FIRST BIOLOGIC APPROVED TO TREAT CLINICAL MANIFESTATIONS OF SLE WHEN ADDED TO STANDARD THERAPY
Superior disease activity reduction (SRI-4) vs standard therapy (ST) alone at Week 521-3
SRI-4 achieved significant improvement
These reductions were primarily related to improvements in the mucocutaneous, musculoskeletal, and immunologic organ domains.
SRI = SLE Responder Index; SC = subcutaneous.
* In BLISS-76, the difference in SRI-4 response rates was not significantly different at Week 76 (secondary endpoint).
DESIGNED TO MEASURE RESPONSE TO LUPUS TREATMENT
The SRI-4 is a combined clinical endpoint used in lupus trials
There were no statistically significant differences between treatment groups in any trial.